

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT

**RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS
TYPE 5 VECTOR) RECOMMENDED AS HETEROLOGOUS VACCINE FOR
BOOSTER DOSE AND ADDITIONAL DOSE IN ARGENTINA**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia) has been recommended by the Ministry of Health of Argentina on its official website to be used in Argentina’s heterologous prime-boost vaccination program for COVID-19 as (a) a booster dose with a minimum interval of six months after the last dose of the primary regimen in healthcare personnel, adults 70 years and older and seniors; and (b) an additional dose with a minimum interval of one month after the last dose of the primary regimen in individuals who are immunocompromised and in adults 50 years and older who were previously vaccinated with inactivated vaccine. For further details of such recommendation, please refer to the official website of the Ministry of Health of Argentina: <https://www.argentina.gob.ar/salud/inmunoprevenibles/recomendaciones-manuales-y-lineamientos>.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, November 15, 2021

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.